Modified General Primer PCR System for Sensitive Detection of Multiple Types of Oncogenic Human Papillomavirus
Overview
Affiliations
Human papillomavirus (HPV) infection is a necessary cause of cervical cancer and cervical dysplasia. Accurate and sensitive genotyping of multiple oncogenic HPVs is essential for a multitude of both clinical and research uses. We developed a modified general primer (MGP) PCR system with five forward and five reverse consensus primers. The MGP system was compared to the classical HPV general primer system GP5+/6+ using a proficiency panel with HPV plasmid dilutions as well as cervical samples from 592 women with low-grade cytological abnormalities. The reference method (GP5+/6+) had the desirable high sensitivity (five copies/PCR) for five oncogenic HPV types (HPV type 16 [HPV-16], HPV-18, HPV-56, HPV-59, and HPV-66). The MGP system was able to detect all 14 oncogenic HPV types at five copies/PCR. In the clinical samples, the MGP system detected a significantly higher proportion of women with more than two concomitant HPV infections than did the GP5+/6+ system (102/592 women compared to 42/592 women). MGP detected a significantly greater number of infections with HPV-16, -18, -31, -33, -35, -39, -42, -43, -45, -51, -52, -56, -58, and -70 than did GP5+/6+. In summary, the MGP system primers allow a more sensitive amplification of most of the HPV types that are established as oncogenic and had an improved ability to detect multiple concomitant HPV infections.
Cervical cancer microbiome analysis: comparing HPV 16 and 18 with other HPV types.
Hidjo M, Mukhedkar D, Masimirembwa C, Lei J, Arroyo Muhr L Sci Rep. 2024; 14(1):22014.
PMID: 39317706 PMC: 11422507. DOI: 10.1038/s41598-024-73317-8.
A pilot study of risk-stratified cervical cancer screening.
Wang J, Elfstrom K, Borgfeldt C, Dillner J Open Res Eur. 2023; 1:84.
PMID: 37645164 PMC: 10445943. DOI: 10.12688/openreseurope.13398.2.
Kristiansen S, Bjartling C, Torbrand C, Grelaud D, Lindstrom M, Svensson A BMC Cancer. 2022; 22(1):1227.
PMID: 36443686 PMC: 9703753. DOI: 10.1186/s12885-022-10324-w.
Basiletti J, Valls J, Poklepovich T, Fellner M, Rol M, Alonso R PLoS One. 2022; 17(11):e0278117.
PMID: 36417453 PMC: 9683586. DOI: 10.1371/journal.pone.0278117.
Co-testing in cervical screening among 40- to 42-year-old women is unreasonable.
Borgfeldt C, Leksell A, Forslund O Acta Obstet Gynecol Scand. 2022; 101(3):374-378.
PMID: 34988970 PMC: 9564562. DOI: 10.1111/aogs.14311.